Phase I Trial of Rosiglitazone in FSGS | Zendy

Melanie S. Joy | Zendy; Debbie S. Gipson | Zendy; Mary Dike | Zendy; Leslie Powell | Zendy; Amber Thompson | Zendy; Suzanne Vento | Zendy; Allison A. Eddy | Zendy; Agnes B. Fogo | Zendy; Jeffrey B. Kopp | Zendy; Daniel C. Cattran | Zendy; Howard Trachtman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase I Trial of Rosiglitazone in FSGS

Author(s) -

Melanie S. Joy,

Debbie S. Gipson,

Mary Dike,

Leslie Powell,

Amber Thompson,

Suzanne Vento,

Allison A. Eddy,

Agnes B. Fogo,

Jeffrey B. Kopp,

Daniel C. Cattran,

Howard Trachtman

Publication year - 2008

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.02310508

Subject(s) - rosiglitazone , medicine , tolerability , kidney disease , urology , adverse effect , renal function , dosing , clinical trial , receptor

Patients with primary focal segmental glomerulosclerosis (FSGS) who are resistant to standard therapy are at high risk for progressive chronic kidney disease. Prevention of renal fibrosis represents a promising strategy to slow or halt kidney function decline. This paper presents the results of a Phase I clinical trial of rosiglitazone, a thiazolidinedione, that exerts antifibrotic effects in animal models of FSGS. The primary goal was assessment of safety, tolerability, and pharmacokinetics (PK) of rosiglitazone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research